The IPO8 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocytic cell line, designed to disrupt the IPO8 gene encoding importin-8. This polyclonal knockout model provides a heterogeneous collection of genetic disruptions, enabling functional studies of nucleocytoplasmic transport without the limitations of clonal selection. It serves as a versatile tool for investigating importin-8-dependent nuclear import in a T-cell context.
Jurkat cells are an immortalized human T lymphocyte line established from a patient with acute T cell leukemia. They are widely employed to study T cell activation, signal transduction, and immune regulation, offering a robust platform for analyzing signaling pathways relevant to both normal T-cell biology and leukemogenesis. Their stable growth and well-characterized signaling make them ideal for genetic perturbation experiments.
IPO8 encodes importin-8, a karyopherin that facilitates translocation of cargo proteins with nuclear localization signals into the nucleus. Importin-8 interacts with RAN GTPase and nucleoporins to mediate transport. Key cargoes include SMAD2/3 and SMAD4 transcription factors, Argonaute-2 (AGO2), and SRY. Importin-8 is activated by TGF-beta receptor signaling and cellular stress, linking it to nucleocytoplasmic shuttling of TGF-beta/SMAD effectors and miRNA machinery components. Thus, IPO8 disruption can impair TGF-beta-induced SMAD nuclear accumulation and AGO2-dependent gene silencing.
In Jurkat cells, TGF-beta signaling regulates activation and may contribute to leukemic transformation. Knocking out IPO8 is predicted to block SMAD nuclear import, attenuating transcriptional responses to TGF-beta. Similarly, defective AGO2 import may dysregulate miRNA-mediated post-transcriptional control. This model enables dissection of importin-8??s role in T-cell signaling networks and leukemia-associated pathways.
These cells are suited for applications such as TGF-beta reporter assays, Western blotting for SMAD localization, immunofluorescence imaging of cargo trafficking, and co-immunoprecipitation to examine importin-8 complexes. Downstream transcriptional profiling via RNA-seq and flow cytometric analyses of T-cell activation markers provide insights into functional consequences of IPO8 loss. The polyclonal format captures population-level variability and facilitates pooled screening approaches. For additional information, please contact Ascent Research.
